Stephen F. Mahoney - 30 Nov 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role: Title: Chief Financial and Operating Officer
Signature: /s/ Cindy Driscoll, Attorney-in-Fact for Stephen F. Mahoney
Issuer symbol: DNTH
Transactions as of: 30 Nov 2022
Transactions value $: $2,820
Form type: 4
Filing time: 02 Dec 2022, 15:23:47
Previous filing: 01 Aug 2022
Next filing: 01 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNTH	Common Stock	Award	$2.82K	+3K	+21.03%	$0.94^*	17.3K	30 Nov 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2	In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Remarks:

Title: Chief Financial and Operating Officer